RT Journal Article
SR Electronic
T1 Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.23.21262472
DO 10.1101/2021.08.23.21262472
A1 Gadani, Sachin P.
A1 Reyes-Mantilla, Maria
A1 Jank, Larissa
A1 Harris, Samantha
A1 Douglas, Morgan
A1 Smith, Matthew D.
A1 Calabresi, Peter A.
A1 Mowry, Ellen M.
A1 Fitzgerald, Kathryn C.
A1 Bhargava, Pavan
YR 2021
UL http://medrxiv.org/content/early/2021/08/25/2021.08.23.21262472.abstract
AB Background Sphingosine-1-phosphate receptor (S1P) modulators and antiCD20 therapies impair humoral responses to SARS-CoV-2 mRNA vaccines. Whether disease modifying therapies (DMTs) for multiple sclerosis (MS) also impact T cell immune response to vaccination is unknown.Methods In 101 people with MS, we measured humoral responses via an immunoassay to measure IgG against the COVID-19 spike S1 glycoprotein in serum. We also measured T cell responses using FluoroSpot assay for interferon gamma (IFN-γ) (Mabtech,Sweden) using cryopreserved rested PBMCs and then incubated in cRPMI with 1µg/ml of pooled peptides spanning the entire spike glycoprotein (Genscript, 2 pools; 158 peptides each). Plates were read on an AID iSpot Spectrum to determine number of spot forming cells (SFC)/106 PBMCs. We tested for differences in immune responses across DMTs using linear models.Findings Humoral responses were detected in 22/39 (56.4%) participants on anti-CD20 and in 59/63 (93.6%) participants on no or other DMTs. In a subset with immune cell phenotyping (n=88; 87%), T cell responses were detected in 76/88 (86%), including 32/33 (96.9%) participants on anti-CD20 therapies. AntiCD20 therapies were associated with an increase in IFN-γ SFC counts relative to those on no DMT or other DMTs (for antiCD20 vs. no DMT: 425.9% higher [95%CI: 109.6%, 1206.6%] higher; p<0.001; for antiCD20 vs. other DMTs: 289.6% [95%CI: 85.9%, 716.6%] higher; p<0.001).Interpretation We identified a robust T cell response in individuals on anti-CD20 therapies despite a reduced humoral response to SARS-CoV-2 vaccination. Follow up studies are needed to determine if this translates to protection against COVID-19 infection.Competing Interest StatementSPG has nothing to disclose MR has nothing to disclose LJ has nothing to disclose SH has nothing to disclose MD has nothing to disclose MDS has nothing to disclose PAC has received consulting fees from Disarm and Biogen and is PI on grants to JHU from Genentech, Principia, and Annexon. EMM reports receiving research funding as site PI or for investigator-initiated studies from Biogen, Genentech, and Teva. She receives royalties for editorial duties from UpToDate. KCF has nothing to disclose PB reports receiving research funding from Genentech, Amylyx pharmaceuticals and EMD Serono and has received honoraria from EMD-Serono and Sanofi-Genzyme. Funding StatementThis study was funded partially by 1K01MH121582-01 from NIH/NIMH and TA-1805-31136 from the National MS Society (NMSS) to KCF and TA-1503-03465 and JF-2007-37655 from the NMSS to PB. This study was also supported through the generosity of the collective community of donors to the Johns Hopkins University School of Medicine for COVID research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Johns Hopkins IRB (IRB00246910)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data may be available upon request for investigators whose proposed use has been approved by the Institutional Review Board (IRB) of institution of the principal investigator.